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any drugs discovered by our prehistoric ancestors are those affecting be-
havior. As this was not the result of an organized search for such agents, it 
reflects the fact that humans notice when consumption of a product alters 
their sensorium. In some cases the effect was perceived as beneficial, whereas in oth-
ers it was dysphoric. Word of these discoveries was passed on for generations. Over 
the millennia, these products were employed for recreational or religious purposes, 
as poisons, for inducing sleep, or for enhancing endurance.  
Defining the behavioral effects of 
chemical substances remains an im-
portant component in the modern era 
(~1850 to the present) of drug discovery. 
Typically agents are sought that provoke 
desirable, or diminish undesirable, be-
haviors. Behavioral test are employed to 
determine whether a drug candidate un-
intentionally modifies central nervous 
system function, with such an action of-
ten being considered a side effect or tox-
icity.  
Given the ongoing need to define 
the behavioral consequences of potential 
pharmaceuticals and environmental 
agents, there is a critical need for re-
search and training in the behavioral sci-
ences. Unfortunately, support for such 
programs has waned. This is due to a 
flagging interest in the field on the part 
of funding agencies, and a decline in the 
hiring of behavioral scientists by the 
pharmaceutical industry. As detailed in 
several publications (Enna and Williams, 
2009 a & b), including an earlier Merrill 
Series report (Enna, 2008), this reflects a 
general shift away from in vivo animal 
experimentation to in vitro assays for 
identifying and characterizing drug 
candidates. Provided below is a brief 
overview of how the behavioral sciences 
have historically played a major role in 
identifying important drugs and drug 
classes, the attempts made to develop 
new assays to substitute for detailed be-
havioral analyses, and efforts now being 
made to resurrect the behavioral scienc-
es as a critical component of the drug 
discovery process.  
Drugs and Behavior 
In foraging for food, ancient hu-
mans would sometimes stumble upon 
plants or animals that provided some-
thing more than nutritional value. Occa-
sionally, poisonous substances would be 
consumed, leading to illness or death. In 
other instances, constituents were in-
gested that had beneficial properties, 
such as anti-inflammatory, analgesic, or 
antimicrobial activity. Such effects 
would be noted only if the individual 
was consciously suffering from a condi-
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tion that was moderated by the product. 
However, the medicinal value might be 
overlooked if a significant amount of 
time elapsed between its consumption 
and the therapeutic effect, as would be 
the case with antibiotics, making it less 
likely the person would relate the posi-
tive response to the ingestion of a par-
ticular foodstuff. It might also be missed 
if days or weeks of continuous admin-
istration were needed for a beneficial 
response. Because the human subject 
was not searching specifically for such 
agents, centuries of consumption might 
pass before therapeutic benefits were 
noted by a sufficient number of individ-
uals to warrant the routine collection of 
a particular plant or animal species for 
such purposes. 
Unlike agents used for treating a 
somatic illness or infectious dis-
ease, the effects of a psychoac-
tive compound are often no-
ticed soon after its consump-
tion, whether or not the indi-
vidual is suffering from a medi-
cal condition. Thus, psychedel-
ics, central nervous system 
stimulants, sedatives, and con-
vulsants would be readily ap-
preciated by the consumer, and 
possibly by those around him, 
because the substance could 
affect behavior. Some agents 
still in use today that were discovered in 
the pre-modern era include morphine, 
psilocybin and other hallucinogens, the 
central nervous system stimulants co-
caine, caffeine, and ephedrine, and etha-
nol, a sedative (Table 1). While the dis-
covery of these substances did not result 
from well-designed behavioral studies, 
their early identification and exploita-
tion by individuals who were scientifi-
cally unsophisticated illustrates the val-
ue of characterizing behavioral effects in 
identifying novel entities for treating 
central nervous system disorders, and 
for predicting certain side effects. 
The serendipitous discovery of use-
ful, centrally-active drugs did not end 
with the pre-modern era. In fact, a sig-
nificant number, if not a majority, of cen-
trally-active agents, and their chemical 
derivatives, that are used today were 
discovered empirically. Examples of 
psychotherapeutics discovered by acci-
dent in the modern era are iproniazide 
and imipramine, antidepressants that 
were originally developed as an an-
titubercular agent and an antihistamine, 
respectively, and chlorpromazine, an 
antipsychotic that was initially tested as 
an adjunct for general anesthesia. The 
therapeutic uses of carbamazepine, an 
anticonvulsant and an analgesic, valpro-
ic acid, an anticonvulsant and treatment 
for bipolar disorder, chlordiazepoxide, 
an anxiolytic and sedative, and 
modafinil, a psychostimulant, were all 
discovered empirically (Table 1).  
These examples, which are only a 
partial list of such drugs, illustrate how 
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keen behavioral observations made by 
astute clinicians and bench scientists 
opened new avenues for treating mental 
illness and other central nervous system 
disorders. For example, prior to the dis-
covery of iproniazide and chlorproma-
zine there were no drugs that could be 
used specifically to treat major depres-
sion or to alleviate symptoms of schizo-
phrenia. Chlordiazepoxide was a semi-
nal discovery in that it revealed a chemi-
cal class, the benzodiazepines, that 
could, at the proper dose, relieve anxiety 
without causing profound sedation. 
Likewise, modafinil revolutionized the 
treatment of narcolepsy by maintaining 
alertness while, unlike amphetamine, 
not profoundly activating central nerv-
ous system activity. 
Discoveries such as these spurred 
training in behavioral research. It was 
appreciated that such expertise was 
needed to understand and categorize 
normal and abnormal human behaviors 
so they could be properly studied in a 
clinical setting. It was also important for 
behavioral scientists to develop labora-
tory animal models of central nervous 
system disorders that could be used in 
drug discovery programs aimed at iden-
tifying new chemical leads. While pro-
gress was made in achieving these goals, 
much remains to be done. In particular, 
there are serious questions about the 
utility of animal models of major de-
pression and psychosis in predicting the 
clinical efficacy of drug candidates. As 
many of these tests are based on behav-
iors induced by agents used to treat the-
se conditions, it is argued that they are 
actually models of drug action, rather 
than of the clinical condition itself. For 
this reason, a drug candidate that dis-
plays possible therapeutic efficacy when 
examined in these models will, more 
than likely, have a cellular mechanism of 
action similar to the established agent, 
lessening its therapeutic impact. Accord-
ingly, it is difficult to use such tests if the 
aim is to identify truly novel drugs for 
treating these conditions. What is need-
ed, therefore, is additional information 
on the underlying neuropathology so 
that it can be induced, and its behavioral 
manifestations catalogued, in laboratory 
animals. As the resultant behaviors 
would have face validity, their modifica-
tion could possibly be used to predict 
therapeutic potential regardless of the 
mechanism of action of the test agent. 
Until such information is accumulated, 
those interested in drug discovery must 
continue to rely on the observations of 
experienced behavioral scientists and 
clinicians for identifying new psycho-
therapeutics. 
The importance of serendipity in the 
discovery of centrally-active agents has 
been acknowledged in the past by in-
cluding a set of behavioral tests in early 
phases of the drug discovery program. 
One such battery was the Irwin test. In-
clusion of a general behavioral screen 
left open the possibility that a neurosci-
entist or pharmacologist would note an 
unusual behavioral response early in the 
drug discovery process. If the com-
pound-induced behavioral modification 
was perceived to have therapeutic po-
tential, additional work could be under-
taken to characterize the effect more ful-
ly to predict its clinical value. In this way 
novel, unanticipated, central nervous 
system effects would be noted and ex-
ploited for therapeutic benefit, as was 
done in a more haphazard manner in the 
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pre-modern and early modern eras of 
drug discovery. 
Decline of Behavioral Research in 
Drug Discovery  
As detailed extensively elsewhere 
(Enna, 2008; Enna and Williams, 2009 a 
& b), there was a significant shift in the 
design of drug discovery programs in 
the latter part of the 20th century. Until 
that time the major emphasis was gener-
ally on first identifying chemicals that 
displayed some type of therapeutic po-
tential in intact animals or organ system 
tests, after which studies were per-
formed to fully characterize their poten-
tial therapeutic efficacy, safety and 
mechanism of action. Of these various 
factors, mechanism of action was least 
important because then, as now, an un-
derstanding of mechanism is unneces-
sary for regulatory approval for human 
use, or for exploiting such an agent for 
clinical benefit. What is critical is that the 
chemical be shown to be safe and effec-
tive in humans.  
This approach to drug discovery 
began to change in the 1980’s, with ini-
tial tests being more focused on identify-
ing chemicals that interact selectively, if 
not specifically, with known or suspect-
ed drug targets in the body. It was only 
after such compounds were identified 
using in vitro tests, that in vivo assays 
were performed to establish efficacy and 
safety in animal models of disorders 
thought to be related to the target site. 
Drug targets include enzymes, neuro-
transmitter and hormone receptors, ion 
channels, and transcription factors. This 
change in the approach to drug discov-
ery from initially identifying compounds 
that display potential therapeutic activi-
ty in animals, to first designing selective 
ligands that interact with sites thought 
to be associated with the disorder of in-
terest, was driven by several factors. 
Among these was the mapping of the 
human genome, which led many to be-
lieve it was just a matter of time before 
the genetic defects for many disorders 
were identified, thereby revealing the 
protein target that needed to be manipu-
lated pharmacologically for therapeutic 
gain. It was also appreciated that in vitro 
screens of chemical libraries were much 
faster, more efficient, and less costly 
than labor intensive in vivo assays, such 
as those associated with behavioral tests. 
In addition, in vitro assays more readily 
lend themselves to automation, thereby 
speeding up the screening process and 
making it possible to test many more 
agents, in much smaller amounts, than 
in vivo assays. Automated tests were also 
appealing as they require fewer skilled 
scientists for execution and data analy-
sis.  
Automated in vivo screens, such as 
SmartCube and Pattern Array, were de-
veloped in an attempt to simplify and 
speed the assessment of test agents on 
animal behavior. These assay systems 
are capable of measuring a host of 
mouse behaviors in a short period of 
time and with little human oversight. By 
comparing quantified behavioral pat-
terns between control animals, those 
administered a test agent, and archival 
data on the behavioral response to know 
centrally-active drugs, it is believed that 
predictions could be made about the be-
havioral effects of the drug candidate. 
While such tests can be an important 
component of a drug discovery pro-
gram, they are not likely to detect an 
unusual response that might be noted by 
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an observant and trained behavioral sci-
entist.  
As a result of this shift in research 
emphasis, the number of scientists 
trained in organ system and behavioral 
pharmacology declined. This was accel-
erated by a number of related develop-
ments, but was driven primarily by 
stagnation, if not an absolute decline, in 
federal funding for research involving 
vertebrate animals (Table 2).  
Because federal funding determines 
to a great extent the nature and direction 
of academic research, investigators be-
came more focused on testing hypothe-
ses relating to molecular 
and bio-chemical mech-
anisms than organ sys-
tems biology and the 
behavioral sciences. Be-
sides taking advantage 
of the great strides being 
made in molecular biol-
ogy, this shift away from 
in vivo assays had practi-
cal consequences in that 
it enhanced competi-
tiveness for funding given the growing 
bias against such studies. As the number 
of funded behavioral scientists declined, 
fewer students pursued graduate work 
in the area. Over time, the cadre of facul-
ty qualified to conduct research and to 
serve as mentors in the behavioral sci-
ences diminished as well, both through 
natural attrition and the reluctance of 
institutions to hire such individuals be-
cause of the challenges they faced in 
garnering grant support (Table 2). This 
downward spiral ultimately lead to a 
shortage of scientists capable of conduct-
ing well-designed, and appropriately 
interpreted, in vivo laboratory animal 
studies in general, and behavioral exper-
iments in particular. Some argue it is no 
coincidence that the loss of this expertise 
coincided with a significant decline in 
the identification of new drug candi-
dates, especially those for the treatment 
of neurological and psychiatric disorders 
(Enna and Williams, 2009a).  
Renaissance 
Over the past decade there has been 
a renewed appreciation of the im-
portance of whole animal studies in bi-
omedical research. This was spurred in 
part by the growing lag time between 
discovery and clinical use of new drugs 
and other therapeutic modalities, and by 
the decline in the number of new prod-
uct approvals in the face of ever increas-
ing investments in drug discovery. To 
address these issues, the National Insti-
tutes of Health (NIH) launched the 
Roadmap program (Zerhouni, 2003) and 
the Food and Drug Administration cre-
ated the Critical Path Initiatives (2004). 
Also, in 2006 the U.S. Government Gen-
eral Accountability Office (GAO) pub-
lished a report detailing factors that slow 
drug discovery and development. 
Among those cited was a decline in the 
ability to translate basic biological dis-
coveries into drugs. In short, the GAO 
tacitly acknowledged that the emphasis 
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on first characterizing molecular mecha-
nisms in the search for new drugs had 
led to erosion in the expertise ultimately 
needed to develop chemical leads into 
viable drug candidates. Among the dis-
ciplines that were becoming underrepre-
sented in this regard were the behavioral 
sciences, and both basic and clinical 
pharmacology.  
The NIH Roadmap is designed to 
speed the rate of drug discovery and the 
dissemination of new therapies 
throughout the medical community. An 
important component of this undertak-
ing is the Clinical and Translational Sci-
ence Awards (CTSA’s) that fund institu-
tional initiatives in these areas. To be 
competitive for a CTSA, applicants are 
encouraged to include service or re-
search components relating to behavior-
al assessments of health care providers, 
patients, or laboratory animals to help 
foster new drug development or the use 
of old drugs for new purposes. Both the 
United Kingdom and countries on the 
European continent have initiated simi-
lar programs. In all cases, it is acknowl-
edged that efforts must be made to re-
establish the importance of in vivo test-
ing, behavioral observations and analy-
sis in the drug discovery process. Be-
cause the expertise necessary for design-
ing such tests is diminishing, funding 
agencies in the United States, United 
Kingdom, and Europe are underwriting 
training programs aimed at exposing 
biomedical scientists to the fundamen-
tals of whole animal research. In the 
United States such efforts are exempli-
fied by the Integrative and Organ Sys-
tem Pharmacology courses underwritten 
by the National Institute of General 
Medical Sciences (Preusch, 2004).  
Conclusion 
As the response to systemically ac-
tive drugs and other xenobiotics typical-
ly involves the interplay of several or-
gans and organs systems, the ability to 
understand such interactions, and to ex-
amine such effects experimentally, is an 
essential component of the drug discov-
ery process. For a time, however, an ob-
session with defining drugs primarily in 
terms of molecular mechanisms led to 
devaluation of whole animal research 
and of detailed pharmacological analysis 
of the effect of test agents on organ sys-
tem function and behavior. Besides the 
negative impact this shift in emphasis 
had on training in the pharmacological 
and behavioral sciences, it is also 
acknowledged to have contributed to a 
decline in the rate of new drug discov-
ery. Given the proven importance of 
empirical observation in identifying 
novel drugs, even in the modern era, this 
consequence is not surprising. The re-
newed appreciation of the importance of 
whole animal and organ system re-
search, and the appropriation of funds to 
reinvigorate training in these areas will 
help redress the imbalance in preclinical 
research emphasis in the search for new 
drugs . The evidence suggests that the 
most efficient and productive biomedi-
cal research programs should include 
equal measures of studies involving 
whole animals and organ systems and 
those aimed at characterizing the bio-
chemical and molecular targets of the 
drug candidates. Those interested in the 
behavioral sciences should be heartened 
by these recent developments as they 
bode well for the future of this, and re-
lated, disciplines.  
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